Triple-drug immunosuppression for heart transplantation in infants and children

John Brown, Mark Turrentine, Kenneth Kesler, Y. Mahomed, R. Darragh, K. Evans, L. Thompson, R. Caldwell

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Triple-drug immunosuppression with OKT3 induction is effective rejection prophylaxis in pediatric cardiac allograft recipients. The concerns regarding prevalent lymphoproliferative disease, growth retardation, cytomegalovirus, and other opportunistic infections have not been realized. Since June 1986, 34 pediatric patients, 23 males and 11 females, (age 4 days to 15 years) have undergone orthotopic heart transplantation at our institution. Fifteen patients were less than 6 months old and 13 had type I or II hypoplastic left heart syndrome. There have been four (12%) operative and four (12%) late deaths and a survival rate of 76% after a mean follow-up of 33 months (range, 1 to 82 months). The only deaths attributed to allograft rejection occurred in two newborn recipients (2 and 10 months after surgery) who neither received maintenance steroids nor underwent routine biopsy. The only death from infection (pneumococcus) occurred 6 months after surgery in a 4-year- old patient who was not known to be asplenic. Of the 27 long-term (> 1 year) survivors, 17 (68%) had an average of two rejection episodes during the follow-up period, 10 patients (32%) have been free of graft rejection, and 26 patients (96%) have not experienced a cytomegalovirus infection despite OKT3 induction therapy. Two patients developed lymphoproliferative disease, one of whom was successfully treated by transient reduction of immunosuppression. The other patient died 13 months after transplantation of a lymphoma of the central nervous system. All survivors have demonstrated satisfactory increases in mean height and weight. No patient has angiographic evidence of coronary artery disease. We conclude that triple-drug immunosuppression with OKT3 induction is an effective antirejection protocol and results in a low incidence of cytomegalovirus, lymphoproliferative disease, and coronary artery disease and an acceptable growth.

Original languageEnglish
JournalJournal of Heart and Lung Transplantation
Volume12
Issue number6 II
StatePublished - 1993

Fingerprint

Heart Transplantation
Immunosuppression
Muromonab-CD3
Pharmaceutical Preparations
Cytomegalovirus
Allografts
Survivors
Coronary Artery Disease
Pediatrics
Hypoplastic Left Heart Syndrome
Opportunistic Infections
Cytomegalovirus Infections
Graft Rejection
Growth
Streptococcus pneumoniae
Lymphoma
Survival Rate
Central Nervous System
Transplantation
Steroids

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Triple-drug immunosuppression for heart transplantation in infants and children. / Brown, John; Turrentine, Mark; Kesler, Kenneth; Mahomed, Y.; Darragh, R.; Evans, K.; Thompson, L.; Caldwell, R.

In: Journal of Heart and Lung Transplantation, Vol. 12, No. 6 II, 1993.

Research output: Contribution to journalArticle

@article{6035682d4f9c4b7bb9fe3dec212a8102,
title = "Triple-drug immunosuppression for heart transplantation in infants and children",
abstract = "Triple-drug immunosuppression with OKT3 induction is effective rejection prophylaxis in pediatric cardiac allograft recipients. The concerns regarding prevalent lymphoproliferative disease, growth retardation, cytomegalovirus, and other opportunistic infections have not been realized. Since June 1986, 34 pediatric patients, 23 males and 11 females, (age 4 days to 15 years) have undergone orthotopic heart transplantation at our institution. Fifteen patients were less than 6 months old and 13 had type I or II hypoplastic left heart syndrome. There have been four (12{\%}) operative and four (12{\%}) late deaths and a survival rate of 76{\%} after a mean follow-up of 33 months (range, 1 to 82 months). The only deaths attributed to allograft rejection occurred in two newborn recipients (2 and 10 months after surgery) who neither received maintenance steroids nor underwent routine biopsy. The only death from infection (pneumococcus) occurred 6 months after surgery in a 4-year- old patient who was not known to be asplenic. Of the 27 long-term (> 1 year) survivors, 17 (68{\%}) had an average of two rejection episodes during the follow-up period, 10 patients (32{\%}) have been free of graft rejection, and 26 patients (96{\%}) have not experienced a cytomegalovirus infection despite OKT3 induction therapy. Two patients developed lymphoproliferative disease, one of whom was successfully treated by transient reduction of immunosuppression. The other patient died 13 months after transplantation of a lymphoma of the central nervous system. All survivors have demonstrated satisfactory increases in mean height and weight. No patient has angiographic evidence of coronary artery disease. We conclude that triple-drug immunosuppression with OKT3 induction is an effective antirejection protocol and results in a low incidence of cytomegalovirus, lymphoproliferative disease, and coronary artery disease and an acceptable growth.",
author = "John Brown and Mark Turrentine and Kenneth Kesler and Y. Mahomed and R. Darragh and K. Evans and L. Thompson and R. Caldwell",
year = "1993",
language = "English",
volume = "12",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "6 II",

}

TY - JOUR

T1 - Triple-drug immunosuppression for heart transplantation in infants and children

AU - Brown, John

AU - Turrentine, Mark

AU - Kesler, Kenneth

AU - Mahomed, Y.

AU - Darragh, R.

AU - Evans, K.

AU - Thompson, L.

AU - Caldwell, R.

PY - 1993

Y1 - 1993

N2 - Triple-drug immunosuppression with OKT3 induction is effective rejection prophylaxis in pediatric cardiac allograft recipients. The concerns regarding prevalent lymphoproliferative disease, growth retardation, cytomegalovirus, and other opportunistic infections have not been realized. Since June 1986, 34 pediatric patients, 23 males and 11 females, (age 4 days to 15 years) have undergone orthotopic heart transplantation at our institution. Fifteen patients were less than 6 months old and 13 had type I or II hypoplastic left heart syndrome. There have been four (12%) operative and four (12%) late deaths and a survival rate of 76% after a mean follow-up of 33 months (range, 1 to 82 months). The only deaths attributed to allograft rejection occurred in two newborn recipients (2 and 10 months after surgery) who neither received maintenance steroids nor underwent routine biopsy. The only death from infection (pneumococcus) occurred 6 months after surgery in a 4-year- old patient who was not known to be asplenic. Of the 27 long-term (> 1 year) survivors, 17 (68%) had an average of two rejection episodes during the follow-up period, 10 patients (32%) have been free of graft rejection, and 26 patients (96%) have not experienced a cytomegalovirus infection despite OKT3 induction therapy. Two patients developed lymphoproliferative disease, one of whom was successfully treated by transient reduction of immunosuppression. The other patient died 13 months after transplantation of a lymphoma of the central nervous system. All survivors have demonstrated satisfactory increases in mean height and weight. No patient has angiographic evidence of coronary artery disease. We conclude that triple-drug immunosuppression with OKT3 induction is an effective antirejection protocol and results in a low incidence of cytomegalovirus, lymphoproliferative disease, and coronary artery disease and an acceptable growth.

AB - Triple-drug immunosuppression with OKT3 induction is effective rejection prophylaxis in pediatric cardiac allograft recipients. The concerns regarding prevalent lymphoproliferative disease, growth retardation, cytomegalovirus, and other opportunistic infections have not been realized. Since June 1986, 34 pediatric patients, 23 males and 11 females, (age 4 days to 15 years) have undergone orthotopic heart transplantation at our institution. Fifteen patients were less than 6 months old and 13 had type I or II hypoplastic left heart syndrome. There have been four (12%) operative and four (12%) late deaths and a survival rate of 76% after a mean follow-up of 33 months (range, 1 to 82 months). The only deaths attributed to allograft rejection occurred in two newborn recipients (2 and 10 months after surgery) who neither received maintenance steroids nor underwent routine biopsy. The only death from infection (pneumococcus) occurred 6 months after surgery in a 4-year- old patient who was not known to be asplenic. Of the 27 long-term (> 1 year) survivors, 17 (68%) had an average of two rejection episodes during the follow-up period, 10 patients (32%) have been free of graft rejection, and 26 patients (96%) have not experienced a cytomegalovirus infection despite OKT3 induction therapy. Two patients developed lymphoproliferative disease, one of whom was successfully treated by transient reduction of immunosuppression. The other patient died 13 months after transplantation of a lymphoma of the central nervous system. All survivors have demonstrated satisfactory increases in mean height and weight. No patient has angiographic evidence of coronary artery disease. We conclude that triple-drug immunosuppression with OKT3 induction is an effective antirejection protocol and results in a low incidence of cytomegalovirus, lymphoproliferative disease, and coronary artery disease and an acceptable growth.

UR - http://www.scopus.com/inward/record.url?scp=0027765656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027765656&partnerID=8YFLogxK

M3 - Article

C2 - 8312346

AN - SCOPUS:0027765656

VL - 12

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 6 II

ER -